Impact of G-CSF Prophweylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma.
Fiche publication
Date publication
mars 2022
Journal
The oncologist
Auteurs
Membres identifiés du Cancéropôle Est :
Pr LEPAGE Côme
Tous les auteurs :
Canton C, Boussari O, Boulin M, Le Malicot K, Taieb J, Dahan L, Lopez A, Lepage C, Bachet JB
Lien Pubmed
Résumé
In metastatic pancreatic adenocarcinoma, few data are available on the use of granulocyte-colony stimulating factor (G-CSF) prophylaxis and its impact on dose-intensity (DI), or the link between DI and progression-free survival (PFS). This study assessed the impact of G-CSF prophylaxis on the DI received by patients and the relationship between full DI and PFS according to chemotherapy regimens.
Mots clés
dose-intensity, granulocyte-colony stimulating factor prophylaxis, metastatic pancreatic adenocarcinoma, progression-free survival, propensity score
Référence
Oncologist. 2022 Mar 15;: